PharmAust (ASX:PAA) achieved a successful outcome in a Phase 2 trial investigating the anti-cancer effects of its monepantel tablets in dogs with treatment naïve B-cell lymphoma.
Following 14 days of monepantel tablet treatment, the veterinarians reported that one-of-six dogs achieved a partial response with a greater than 60% reduction in total tumour burden and with one lymph node tumour regressing completely. Four dogs achieved stable disease and progressive disease was seen in one dog.
This outcome provides a meaningful trend, comparing favorably with the treatment used in the original liquid monepantel formula reported in December 2017, where six-of-seven dogs achieved stable disease and progressive disease was seen in one dog.
“Monepantel appears to be showing anti-cancer activity in dogs with lymphoma and I believe that controlled Phase 3 trials are now warranted to investigate the efficacy and safety of lower dose monepantel,” Dr. Claire Cannon, the principal investigator., said in a statement.
“The Phase 2 trial results suggest that monepantel, perhaps in combination with standard-of -care lymphoma therapy, may represent a future prospect for treatment of dogs with this disease,” she added. The current trial has provided a strong basis for further evaluation of this new approach to canine cancer therapy.
